健肝颗粒联合恩替卡韦治疗乙肝肝硬化代偿期的临床疗效观察  

Clinical Study of Jiangan Granule in Treatment of Compensatory Cirrhosis of Hepatitis B

作　　者：李媛 龙富立[1] 张衎[1] 官志杰[1] 姚凡[1] 彭云鹤 舒发明 唐春回 郑艺[1] 黄古叶[1] LI Yuan;LONG Fuli;ZHANG Kan;GUAN Zhijie;YAO Fan;PENG Yunhe;SHU Faming;TANG Chunhui;ZHENG Yi;HUANG Guye(The First Affiliated Hospital of Guangxi University of Chinese Medicine, Nanning 530012 China;Guangxi Key Laboratory of Transmission Medicine for Treating High-Incidence Infectious Diseases with Integrative Medicine, Nanning 530023, China;The Ethnic Hospital of Guangxi Bama Yao Autonomous County, Hechi 547500, China)

机构地区：[1]广西中医药大学第一附属医院,广西南宁530012 [2]广西高发传染病中西医结合转化医学重点实验室培育基地,广西南宁530023 [3]广西巴马瑶族自治县民族医院,广西河池547500

出　　处：《中医药学报》2022年第6期77-80,共4页Acta Chinese Medicine and Pharmacology

基　　金：广西自然科学基金面上项目(2018GXNSFAA138077,2019GXNSFBA245018)。

摘　　要：目的:研究健肝颗粒联合恩替卡韦治疗乙肝肝硬化代偿期临床疗效。方法:60例乙肝肝硬化代偿期患者分为对照组和观察组,两组患者均口服恩替卡韦进行治疗,观察组增服健肝颗粒,为期3个月。采用全自动生化仪检测谷丙转氨酶(ALT)、谷草转氨酶(AST)、总胆红素(TBil)和白蛋白(ALB),放射免疫分析法检测透明质酸(HA)、层连蛋白(LN)、Ⅲ型前胶原肽(PCⅢ)和Ⅳ型胶原(Ⅳ-C),使用Fi-broscan检测肝脏硬度值。结果:相较于治疗前,对照组和观察组治疗后的ALT、AST、TBil、HA、LN、PCⅢ和Ⅳ-C水平及肝脏硬度值均明显下降(P<0.05),ALB水平明显升高,差异有统计学意义(P<0.05);相较于对照组治疗后,观察组治疗后的ALT、AST、TBil、HA、LN、PCⅢ和Ⅳ-C水平及肝脏硬度值均明显下降,ALB水平明显升高(P<0.05)。结论:健肝颗粒联合恩替卡韦治疗乙肝肝硬化代偿期疗效显著,可有效改善肝功能,有抗肝纤维化作用。Objective: To study the clinical efficacy of Jiangan Granule combined with Entecavir in the treatment of compensatory cirrhosis of hepatitis B. Methods: 60 patients with compensatory cirrhosis of hepatitis B were randomly divided into the control group and the observation group. The two groups were treated with Entecavir, and the observation group was also treated with Jiangan Granule. The treatment duration was 3 months. Automatic biochemical analyzer was used to detect glutamic transferase(ALT), aspartate aminotransferase(AST), total bilirubin(TBil) and albumin(ALB);radioimmunoassay was used to detect hyaluronic acid(HA), laminin(LN), type Ⅲ procollagen peptide(PC Ⅲ) and type Ⅳ collagen(Ⅳ-C);liver stiffness was detected by Fibroscan. Results: Compared with those before the treatment, the levels of ALT, AST, TBil, HA, LN, PC Ⅲ and Ⅳ-C and liver stiffness were decreased significantly, and the level of ALB was increased significantly after the treatment in the control group and in the observation group(P<0.05);of which the improvements were more significant in the observation group(P<0.05). Conclusion: The therapy of Jiangan Granule combined with Entecavir has a significant curative effect on compensatory cirrhosis of hepatitis B, and it can effectively improve liver function and resist liver fibrosis.

关 键 词：健肝颗粒 乙型肝炎 肝硬化 肝功能 肝纤维化 

分 类 号：R256.4[医药卫生—中医内科学]